Leqembi Treatment Infrastructure: If Medicare Pays For It, They Will Come
Testing, Infusion Capacity Next Hurdles For Anti-Amyloid Drug
The biggest barrier for Eisai/Biogen’s Alzheimer’s medicine Leqembi was Medicare. With full US FDA approval and Medicare coverage in place, PET scan, MRI and infusion centers are needed to facilitate treatment.
